TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03487042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% ophthalmic solution
Description: Each patient will be subjected to the following:~One side will be treated by narrow band ultraviolet rays B sessions twice weekly for 3 months + topical bimatoprost 0.03% solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays B sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months.~Patients' Evaluation:~The recruited patients will be subjected to:~A) Full history taking. B) General clinical examination. C) Dermatological examination of the skin lesions. D) Vitiligo area scoring index score will be calculated for each patient E) Clinical photographs will be taken at baseline, after each month during treatment and after the end of treatment by 3 months.~F) A skin biopsy from the treated lesions for histochemical examination. F) Dermoscopic evaluation of the treated sites every 2 weeks.
Study: NCT02881086

Intervention type: DRUG
Group type: OTHER
Intervention: Nelarabine
Study: NCT04182997

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
Study: NCT01580592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 150mg, s.c., every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 300mg, s.c., every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, s.c., every 4 weeks
Study: NCT01457118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102 145 mg/m2
Description: A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102 120 mg/m2
Description: A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102 95 mg/m2
Description: A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102 50 mg/m2
Description: A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
Study: NCT01388582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Description: 10 women will receive the LNG-IUS during breastfeeding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implanon
Description: 60 mcg/day contraceptive implant
Study: NCT02881086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Asparaginase
Study: NCT00907621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture with Seirin 020x15 mm sterile acupuncture needle
Description: Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
Study: NCT01388582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mcg EE and 150 LNG oral contraceptive (Microvlar)
Description: 10 women will receive oral contraceptive during breastfeeding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCu380A copper-intrauterine device
Description: Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCu380A intrauterine device
Description: 10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCu380A intrauterine device
Description: 10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCu380A intrauterine device
Description: 10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCu380A intrauterine device
Description: 10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
Study: NCT02162485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler with charcoal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus with charcoal
Study: NCT01841424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling. Maintain a food diary.
Description: The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
Study: NCT04484779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IIM System
Description: IIM System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro and/or Insulin Glargine
Description: Administered subcutaneously (SC)
Study: NCT01395095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation+telephonic coaching
Description: intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTICARE-B
Description: standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTICARE-C
Description: (a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
Study: NCT00786032

Intervention type: DEVICE
Intervention: BCI Device
Description: A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
Study: NCT02084836

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Study: NCT03617133

Intervention type: RADIATION
Group type: OTHER
Intervention: Increased use of IC/IS technique in BT
Description: In EMBRACE II, the improved therapeutic window (through increased application of IC/IS) will be exploited for tumour dose-(de-)escalation and/or OAR dose de-escalation. In tumours with large residual CTVHR volumes at time of brachytherapy, dose-escalation has the potential to improve local control significantly. In limited size CTVHR volumes dose-de-escalation will be performed since dose de-escalation has minor impact on local control while it has potential to reduce morbidity. The strategy of EMBRACEII is to aim for an application of the IC/IS technique in at least 20% of the patients in each institution. The threshold of 20% is relevant for a classical stage distribution of \~20% IB, \~50% IIB, \~20% IIIB and \~10% others. If a given patient population includes significantly higher proportions of limited or extensive disease, the threshold of 20% IC/IS applications must be adapted.
Study: NCT03859778

Intervention type: OTHER
Intervention: survey
Description: French pharmacy students will be contacted by email thanks to the student associations and scolarity departments. Answer to the survey will be done online
Study: NCT03889106

Intervention type: DRUG
Intervention: Ribavirin
Description: Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
Study: NCT02055417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Approaches to Treatment Choices for HIV
Study: NCT04314622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00406796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
Study: NCT02623244

Intervention type: PROCEDURE
Intervention: Laparoscopic oophorocystectomy or oophorectomy
Study: NCT04069442

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study
Study: NCT02055417

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Reduction Skills Program
Study: NCT01956383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device
Description: PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
Study: NCT01793389

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subepithelial connective tissue graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Study: NCT04339738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, spiral CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, spiral CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, spiral CT
Study: NCT02918786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high-flow
Description: After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
Study: NCT01291290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet
Description: 2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
Study: NCT03774914

Intervention type: DRUG
Intervention: Alemtuzumab (GZ402673)
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
Study: NCT04344613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABODpoct device
Description: The device has been developed by a consortium including the Université Libre de Bruxelles, research centers (SIRRIS, CER), a private company (CISEO), and the spin-off Antigon S.A..The device includes a reader and a disposable disk (ABOD disk) for testing one patient et a blood bag. Four blood drops from the patient are deposited on one side of the disk and 4 blood drops from the blood bag one the other side. The disk correctly filled is inserted in the reader and after 2 minutes the result is displayed on the screen as a message GO or No GO. In case of incompatibility or any other problem a red Stop message will appear on the screen.
Study: NCT04416971

Intervention type: PROCEDURE
Intervention: AVF puncture
Description: For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.

Intervention type: PROCEDURE
Intervention: AVF puncture
Description: For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.
Study: NCT04104698

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative EEG
Description: 1. Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~2. Both groups will be assessed for psychological \& cognitive contributes respectively using:~   A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~3. Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~4. The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative EEG
Description: 1. Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~2. Both groups will be assessed for psychological \& cognitive contributes respectively using:~   A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~3. Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~4. The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed.
Study: NCT04339738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET
Study: NCT04544761

Intervention type: OTHER
Intervention: Structured Interview
Description: Structured interview with research staff about your experience living with spinal cord injury

Intervention type: OTHER
Intervention: Structured Interview
Description: Structured interview with research staff about your experience living with spinal cord injury

Intervention type: OTHER
Intervention: Structured Interview
Description: Structured interview with research staff about your experience living with spinal cord injury
Study: NCT04538755

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo before sleep

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAW2020 oral capsule
Description: DAW2020 34 mg 4 h before sleep, single night administration
Study: NCT02854319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOTUS Edge Valve System
Description: Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
Study: NCT04162119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-PD1-CART Cell
Description: This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.
Study: NCT01807858

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium lactis
Description: 5 billion active Bifidobacterium lactis

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium lactis
Description: 5 billion active Bifidobacterium lactis

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium lactis
Description: 5 billion active Bifidobacterium lactis

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium lactis plus İnülin
Description: 5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium lactis plus İnülin
Description: 5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium lactis plus İnülin
Description: 5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: İnulin
Description: 900 mg inulin per day will be given

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: İnulin
Description: 900 mg inulin per day will be given

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: İnulin
Description: 900 mg inulin per day will be given
Study: NCT02825225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 core-biopsy fragments
Description: Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 core-biopsy fragments
Description: Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Base and apex local anesthesia
Description: Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Base and apex local anesthesia
Description: Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
Study: NCT01885845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excellent BRASSS-V Drape™.
Description: Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect weight assesment of blood loss
Description: Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml.
Study: NCT04307316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACBT group
Description: ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Chest percussion, deep breathing, Huff and cough. Early mobilization